News

Sperogenix Therapeutics, the company’s rare disease partner in China, filed the application with the NMPA. The Center for Drug Evaluation (CDE) of the NMPA accepted the filing after

This collaboration is expected to leverage Cipla’s extensive distribution network to enhance the reach of Sanofi India’s CNS products. Under the agreement, Cipla will handle the distribution and

With the deal closing, the merged business will now function under the name Q32 Bio. Concurrent with the merger’s closure, Q32 Bio also finalised a $42m private placement.

This endorsement is a significant step towards the availability of Fabhalta for PNH patients in Europe. The positive opinion is based on data from two Phase III clinical

This development marks the first nonsteroidal medication authorised to treat DMD patients with all genetic variants of a rare neurological disorder. A histone deacetylase (HDAC) inhibitor, Duvyzat can

EVO756 is a highly selective small molecule antagonist targeting mas-related G-protein coupled receptor X2 (MRGPRX2), a receptor implicated in various inflammatory conditions. This partnership builds on a previous

This kinase inhibitor is indicated to be used in combination with chemotherapy in adult patients with newly diagnosed Ph+ ALL. The approval was based on the treatment regimen

The acquisition is a significant step in AstraZeneca’s strategy to transform cancer treatment by offering more targeted therapies as alternatives to traditional treatments like chemotherapy and radiotherapy. RCs,

Abecma is a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell immunotherapy. The ODAC validated the favourable benefit/risk profile of the therapy based on findings from the Phase